Vol. 7, 1972

Pharmacology

International Journal of Experimental and Clinical Pharmacology

Editors

B. B. Brodie, Bethesda, Md.
R. Domenjoz, Bonn
E. Vesell, Hershey, Pa.

Editioral Staff

G. L. Gessa, Cagliari
B. Holmstedt, Stockholm
K. Karzel, Bonn
O. Kraupp, Wien
P. Lechat, Paris
E. G. McQueen, Dunedin
K. Mörsdorf, Bonn
F. Sjöqvist, Stockholm
G. Zbinden, Zürich
G. Zetler, Lübeck

S. Karger · Basel · München · Paris · London · New York · Sydney

S. Karger · Basel · München · Paris · London · New York · Sydney
Arnold Böcklin-Strasse 25, CH-4011 Basel (Switzerland)

All rights, including that of translation into other languages, reserved.
Photomechanic reproduction (photocopy, microcopy) of this book or parts thereof without special permission of the publishers is prohibited.

© Copyright 1972 by S. Karger AG, Verlag für Medizin und Naturwissenschaften, Basel
Printed in Switzerland by Buchdruckerei Friedrich Reinhardt AG, Basel

Contents

Abd-El-Samie, Y.: see Geumei, Aida

Abraham, G. J. S. and Agshikar, N. V.: Anti-Inflammatory Activity of an Essential Oil from *Zanthoxylum budrunga* 109

Agshikar, N. V.: see Abraham, G. J. S.

Asberg, Marie and Germanis, Mirdza: Ophthalmological Effects of Nortriptyline. Relationship to Plasma Level 349

Astrada, C. A.: see Nasello, A. G.

Azarnoff, D. L.: see Shoeman, D. W.

Bergan, T. and Øydvin, B.: Pharmacokinetics of Josamycin – A New Macrolide Antibiotic 36

Bizzi, A.; Tacconi, M. T.; Medea, A., and Garattini, S.: Some Aspects of the Effect of Nicotine on Plasma FFA and Tissue Triglycerides 216

Borgå, O.; Garle, M., and Gutová, Marcela: Identification of 5-(3,4-Dihydroxyphenyl)-5-Phenylhydantoin as a Metabolite of 5,5-Diphenylhydantoin (Phenytoin) in Rats and Man 129

Bourne, H. R.: see Schönhöfer, P. S.

Brodie, B. B.: see Tozer, T. N.

Caster, W. O.: see Wade, A. E.

Chiou, C. Y.: Antagonisms of Hexamethonium Actions by Choline 315

Cooper, P. D.: The Neuromuscular Blocking Action of Diphenylphosphorylcholines 292

Daroqui, Marta R. and Orsingher, O. A.: Effect of α-Methyl-Tyrosine Pretreatment on the Drug-Induced Increase of Hippocampal RNA 366

Dequeker, J.; Heylen, H.; Van Steenkiste, J., and Vroninex, R.: Urinary Total Hydroxyproline, Calcium and Phosphorus Excretion after Administration of Calcium and Oestrogen to Postmenopausal Women 321

De Rinaldis, P.: see Fumarola, D.

Di Carlo, F. J.: see Vesell, E. S.

Domenjoz, R.: see Mörsdorf, K.

Dyer, D. C.; Gant, D. W., and Park, M.: Actions of Histamine on Human, Sheep and Monkey Umbilical Vasculature 101

Elliott, H. W.: see Halliday, Betty

Epps, J. E.: see Vesell, E. S.

Ferraro, D. P.; Lynch, W. C., and Grilly, D. M.: Behavioral Effects of Small Oral Doses of Marihuana Extract in Chimpanzees 273

Forsyth, R. P.: see Miller, R. L.

Fregnan, G. B.: The Inhibitory Effect of Metergoline (an Anti-5-Hydroxytryptaminic Agent) on Rabbit Platelet Aggregation 115

Fumarola, D.; Marcuccio, L., and De Rinaldis, P.: Effect of Leucogenenol on Human Peripheral Lymphocyte Cultures 12

GANT, D. W.: see DYER, D. C.
GARATTINI, S.: see BIZZI, A.
GARLE, M.: see BORGÅ, O.
GERMANIS, MIRDZA: see ÅSBERG, MARIE
GEUMEI, AIDA; ISSA, I., and ABD-EL-SAMIE, Y.: Effects of β-Adrenergic Receptors Stimulation and Blockade on Gastric Acid Secretion in Pigeons 29
GÖRÖG, P. and KOVÁCS, IREN B.: Inhibitory Effect of Phenformin in Adjuvant Arthritis of the Rat 96
GRILLY, D. M.. see FERRARO, D. P.
GUTOVÁ, MARCELA: see BORGÅ, O.
HALLIDAY, BETTY and ELLIOTT, H. W.: Effects of Morphine and Calcium on Respiration of Rat Brain Slices 1
HEYLEN, H.: see DEQUEKER, J.
ISSA, I.: see GEUMEI, AIDA
JACOB, W. H.: see SANDERS, R. B.
JAQUES, R.: see RÜEGG, M.
JORI, A.; PUGLIATTI, C., and SANTINI, V.: Differences in Microsomal Enzyme Induction between Sprague-Dawley and Long-Evans Rats 296
KNIPPERTZ, T.: see MÖRSDORF, K.
KOCH-WESER, J.: see ZACEST, R.
KOLODEJ, A.: see KOWALEWSKI, K.
KOSTOWSKI, W.; REWERSKI, W., and PIECHOCKI, T.: II. The Effects of Some Hallucinogens on Aggressiveness of Mice and Rats 259
KOVÁCS, IREN B.: see GÖRÖG, P.
KOWALEWSKI, K. and KOLODEJ, A.: Potentiation between Pentagastrin and Histamine in Stimulation of Secretion from Totally Isolated *ex vivo* Canine Stomach 357
KOWALEWSKI, K. and SAAB, M.: Potentiation between Pentagastrin and Bethanechol Chloride in Stimulation of Gastric Secretion from Isolated *ex vivo* Canine Stomach Perfused with Homologous Blood 225
KRISHNA, G.: see SCHÖNHÖFER, P. S.
LIEBER, C. S.: see PIROLA, R. C.
LYNCH, W. C.: see FERRARO, D. P.
MARCUCCIO, L.: see FUMAROLA, D.
MEDEA, A.: see BIZZI, A.
MELMON, K. L.: see MILLER, R. L.
MENDE, T. J.: Enhancement of the Antihemostatic Effect of Acetylsalicylic Acid by Ring Iodination 249
MILLER, R. L.; FORSYTH, R. P., and MELMON, K. L.: Morphine-Induced Redistribution of Cardiac Output in the Unanesthetized Monkey 138
MONTINI, E. E.: see NASELLO, A. G.
MÖRSDORF, K.; KNIPPERTZ, T.; RAUSCH, K. D., and DOMENJOZ, R.: Studies on the Antiphlogistic Activity of Cytostatics 209
NASELLO, A. G.; MONTINI, E. E., and ASTRADA, C. A.: Effect of Veratrine, Tetraethylammonium and Diphenylhydantoin on Potassium Release by Rat Hippocampus 89

O'Reilly, R. A.: Vitamin K and Oral Anticoagulant Drugs as Competitive Antagonists in Man 149
Orsingher, O. A.: see Daroqui, Marta R.
Øydvin, B.: see Bergan, T.
Park, M.: see Dyer, D. C.
Passananti, G. T.: see Vesell, E. S.
Paton, D. M.: Metabolic Requirements for the Uptake of Noradrenaline by Isolated Atria and Vas Deferens of the Rabbit 78
Piechocki, T.: see Kostowski, W.
Pirola, R. C. and Lieber, C. S.: The Energy Cost of the Metabolism of Drugs, Including Ethanol 185
Pugliatti, C.: see Jori, A.
Raberger, G. and Weissel, M.: The Effects of Etafenone on the Coronary and Femoral Circulations before and after Adrenergic β-Blockade in Intact Dogs 264
Rangno, R. E.: see Shand, D. G.
Rausch, K. D.: see Mörsdorf, K.
Rewerski, W.: see Kostowski, W.
Riesterer, L.: see Rüegg, M.
Roberfroid, M. B.: see Tozer, T. N.
Rüegg, M.; Riesterer, L., and Jaques, R.: Increase of Plasma Fibrinolysis by Ethyl-tri-O-benzyl-D-glucofuranoside 51
Saab, M.: see Kowalewski, K.
Sanders, R. B. and Jacob, W. H.: Action of Epinephrine on Amino Acid Uptake into Rat Diaphragm *in vitro* and *in vivo* 327
Santini, V.: see Jori, A.
Schlosser, Lucie: see Zetler, G.
Schönhöfer, P. S.; Skidmore, I. F.; Bourne, H. R., and Krishna, G.: Cyclic 3',5'-AMP Phosphodiesterase in Isolated Fat Cells. Simple and Sensitive Methods for the Assay of Phosphodiesterase Activity in Fat Cells and Studies of the Enzyme Inhibition by Theophylline 65
Seidel, G.: see Wendel, U.
Shand, D. G. and Rangno, R. E.: The Disposition of Propranolol. I. Elimination during Oral Absorption in Man 159
Shoeman, D. W. and Azarnoff, D. L.: The Alteration of Plasma Proteins in Uremia as Reflected in their Ability to Bind Digitoxin and Diphenylhydantoin 169
Singbartl, G.: see Zetler, G.
Skidmore, I. F.: see Schönhöfer, P. S.
Tacconi, M. T.: see Bizzi, A.
Tozer, T. N.; Roberfroid, M. B., and Brodie, B. B.: Rate of Norepinephrine Synthesis after Tyramine-Induced Depletion of Norepinephrine in Rat Heart 283
Tseng, L. F. and Walaszek, E. J.: Blockade of *D*-Amphetamine-Induced Stereotyped Behavior by Bulbocapnine 255
Van Steenkiste, J.: see Dequeker, J.

VESELL, E. S.; PASSANANTI, G. T.; VIAU, J.-P.; EPPS, J. E., and DI CARLO, F. J.: Effects of Chronic Prazepam Administration on Drug Metabolism in Man and Rat 197
VIAU, J.-P.: see VESELL, E. S.
VRONINKX, R.: see DEQUEKER, J.
WADE, A. E; WU, BETTY, and CASTER, W. O.: Relationship of Dietary Essential Fatty Acid Consumption to Hepatic Drug Hydroxylation 305
WALASZEK, E. J.: see TSENG, L. F.
WEISSEL, M.: see RABERGER, G.
WENDEL, U. and SEIDEL, G.: Kinins – Evidence for the Involvement in Lymphostatic Encephalopathy in Rats 17
WU, BETTY: see WADE, A. E.
ZACEST, R. and KOCH-WESER, J.: Relation of Propranolol Plasma Level to β-Blockade during Oral Therapy 178
ZETLER, G.; SINGBARTL, G., and SCHLOSSER, LUCIE: Cerebral Pharmacokinetics of Tremor-Producing Harmala and Ibooga Alkaloids 237

Book Reviews 62, 126, 207, 271, 371
News 375
Subject Index 376

Subject Index

Absorption 44, 118, 178, 273
Absorption characteristics of a drug 165
Absorption mechanisms 55
Absorption of bishydroxycoumarin 181
Acetaminophen (blood level and urinary excretion) 190
Acetazolamide 368
Acetylsalicyclic acid 321
ACTH 280
Age and sex in drug metabolism 273
Age dependency of actions 321
Albumin space 181
Allopurinol 259
Alloxanthine 259
Aminopyrine 273
Amphetamine 300
Analgesia 329
Aniline hydroxylase 217
Animals as a secondary standard 55
Antibacterial drug 178
Antibiotics 336
Anticoagulant effect 181
Antidepressive agents 329
Antihistamines 118
Antineoplastic agents 311
Antinociceptive effect 329
Anti-oedematous activity 321
Aspirin 55, 118
Azepinoindoles 235

BAL 232
Barbiturates 21, 181, 222
Benzpyrene hydroxylase 222
Binding sites on plasma albumin 181
Binding to plasma albumin 181
Bile 244
Bioassay 33
Bioavailability 33
Bioavailability/dissolution rate correlations 190
Bioavailability evaluations by blood level determinations 201
Bioavailability of a drug product 204
Bioavailability of drugs 21, 153
Bioavailability of solid oral dosage forms 190
Bioavailability pattern 201
Bioavailability potential 55
Bioavailability requirements 206
Bioavailability standards 55, 211
Bioavailability status 33
Bioavailability studies in man 102
Bioavailability testing 118
Biochemical bioavailability 201
Biologic availability of drug formulations 178
Biologic availability of nitrofurantoin formulations 178
Biometrical considerations 44
Biopharmaceutical assessment 33
Biopharmaceutics of nitrofurantoin 178
Bishydroxycoumarin 181
Blind (or double-blind) technique 44
Blood level studies 55
Bradykinin 353
Brain, catecholamines 291
Bromsulfonephthalein 118

Canadian experience 190
Carbonic anhydrase 368
Cardiac actions 235
Catecholamine 361
Catecholamines, cerebral 291
Cationic drugs 118
Chemical ionization 142
Chlorothiazide (urinary excretion) 190
Chronotropic actions 235
Cinchophen 321
Clearance 118
Clinical effectiveness 33

Closed loop method 55
Comparability and consensus 199
Comparisons 44
Congestive heart failure 118
Cost/availability ratio 102
Coumarin moiety 181
Cyclic AMP phosphodiesterase 280
Cyclic voltametry 142
Cytochrome P-450 217

Data collection 44
Deaggregation 55
Deaggregation of drug particles 55
Definition of bioavailability 44
Desmethylimipramine 118
Development of the bioavailability study 190
Dialysis 244
Diazepam 118
Dibutyryl cyclic AMP 280
Dichlorphenamide 368
Dicoumarol 118
Dilantin plasma levels 163
1,4-Dimethyl-5-phenyl-2-imidazolone 217, 222
Diphenylhydantoin 118, 163
Diphenylhydantoin plasma levels 163
Disintegration standards 201
Dissociation constant (pKa) 21
Dissolution 44, 55, 118
Dissolution and absorption processes 118
Dissolution apparatus 190
Dissolution determinations 154
Dissolution rate data 190
Dissolution-rate measurements 55
Dissolution-rate studies on tablets of sodium warfarin 181
Dissolution requirements of the USP 204
Dissolution tests 55, 190
Disposition curve 118
Distribution 178
Dosage forms 153
Dosage form effects 33
Dosage form factors 118
Dose-response curve 33
Dopamine 361
^{14}C-Dopamine 291
Drug absorption 21
Drug biotransformation 33
Drug concentrations in biologic fluids 22
Drug contamination 33
Drug disintegration and dissolution 178
Drug-dissolution 21
Drug distribution 311
Drug distribution in obesity 118
Drug efficacy and safety 215
Drug efficacy study 215
Drug interaction, prostaglandin 353
Drug interaction and bradykinin 353
Drug metabolism 217, 273, 311
Drug monitoring 33
Drug permeability 21
Drug quality 199
Drug requirements 204
Drug safety 204
Drug solution 21

EACA 300
Effects of disease on bioavailability 33
Electric measurements 142
Electron paramagnetic resonance device 142
Elimination 21, 178
Elimination kinetics 33
Enterohepatic cycling 118
Enzymes 244
Estimation of bioavailability 102
Ethoxyzolamide 368
Ethylmorphine N-demethylase 217
Evaluation of absorption 163
Everted intestine 55
Excretion 33
Excretion products 163
Experimental model 44

Fat cells 280
First-pass effect 118, 344
Flufenamic acid 321
Fluorescence analyses 142
Food and Drug Administration 206
Fourier transform analysis 142

Gas chromatography 142
Gastric absorption 21

Gastric acidity 55
Gastrointestinal barrier 21
Gastrointestinal factors 118
Generic drugs 215
Glucose 244
Gout therapy 259
GPA 1851 217, 222
Guanethidine 300

Half-life 118
Half-life in the blood 44
Harmane 235
Harmine 235
Hepatic extraction 344
Hepatic metabolism 118
Hereditary resistance to oral anti-coagulants 181
Hydrochlorothiazide (urinary excretion study) 190
4-Hydroxycoumarin 181
p-Hydroxynorephedrine 361
4-Hydroxypropranol 118
Hyperthyroidism 118

Iboga alkaloids 235
Ibogamine 235
Imipramine 329
Indole alkaloids 235
Indomethacin 321
Induction of hepatic enzymes 181
Infusion of nicotinic acid 244
Inhibition of drug metabolism 222
Inotropic actions 235
In situ methods 55
Insulin 280
Intestinal metabolism 55
Intrinsic dissolution rate 21
Intrinsic permeability 21
In vitro animal models 55
In vitro dissolution 154
In vitro drug-release procedures 118
In vitro measurements on disintegration 55
In vitro physical methods 55
In vitro test methods 33
In vivo absorption parameters 55
In vivo/in vitro correlations 55
In vivo studies of bioavailability 44
Ionization 21

Josamycin 336
Josamycin, pharmacokinetics 336

Kinetic analysis 55

Labeling technique 142
Legislation for obligatory generic prescribing 215
Lidocaine 118
Light absorption methods 142
Lipid solubility 21
Lipolysis 280
Lithium 329
Liver disease, drug metabolism 336
Liver perfusion 244
Loo-Riegelman method 118

Macrolides, josamycin 336
Mass spectrometer 142
Measurement of mass 142
Mechanisms of drug action 201
6-Mercaptopurine 311
Mesenteric vein preparation 55
Metabolic disposition 163
Metabolism kinetics 118
α-Methyldopa 300
Methylisoxazole carboxylic acid 280
Methylpyrazole carboxylic acid 280
'Microenvironment' 55
Micronization 21
Microsomes 311
'Miniature' pig 55
Mixed function oxidases 217
Molecular weight 142
Morphine 329
Morphine analgesia 329
α-MT 300
Mucosa 21

Narcotic analgesics 118
National formulary 199
Nicotinic acid 280
Nitrofurantoin 178
Nitrofurantoin absorption 178
Nitrofurantoin biologic availability 178

Nitrofurantoin blood concentration 178
Nitrofurantoin clearance 178
Nitrofurantoin excretion 178
Nitrofurantoin half-life 178
Nitrofurantoin study (blood level and urinary excretion) 190
Nitrofurantoin transfer 178
1-[(5-Nitrofurfurylidene)amino]hydantoin 178
Noradrenaline 280
Norepinephrine 361
^{14}C-Norepinephrine 291
^{14}C-Normetanephrine 291
Nortriptyline 118
Nuclear magnetic resonance 142

Official compendia 204
Open perfused intestine 55
Optical rotatory dispersion 142
Oxyphenbutazone 321

Parasympatholytics 118
Particle size 55
pH partition hypothesis 55
pH partition theory 21
Pattern of absorption 201
Peripheral NE 300
Peristaltic activity 118
Pharmacogenetic example 181
Pharmaceutical formulation 33
Pharmaceutical industry 201
Pharmacokinetics 178
Pharmacokinetic models 102
Pharmacokinetic techniques 33
pH at the membrane surface 21
Phenobarbital 118
Phenothiazines 118
Phenylbutazone 21, 154, 181, 190, 321
Phenylindandione 201
Physical *in vitro* methods 55
Physicochemical methods in bioavailability studies 142
Physicochemical properties of drugs 55
Physiologic availability 181
Placebos 44
Plasminogen activation 232
Plasminogen, human 232
Plateau concentrations 33
Polarographic analysis 142
Potassium 244
Potentiation of barbiturates 222
Probenecid, disposition 259
Probenecid, interaction 259
Probenecid, metabolism 259
Profession of medicine 211
Profession of pharmacy 208
Propranolol 118
Propranolol disposition 344
Prostaglandins 353
Protein-binding fractions 118
Protriptyline 329
Psychoses, catecholamines 291
Public interest 33

Quantitation of pharmacologic effects 33
Quinidine 235

Radiation hazards 142
Radioimmunoassay methods 142
Radioisotope experiments 142
Random assignment of subjects 44
Rat 244
Rate-limiting steps of membrane transport 55
Rate of dissolution 118
Refractory period 235
Release from hard capsules 55
Reliability 44
Reserpine 300
Risk-benefit ratio 33

Salicylamide 55, 118
Scatchard plot 181
Scopolamine 291
Significance of bioavailability 199
Single-dose studies 33
SKF 525A 222
Sodium warfarin 181
Solid dosage form 118
Solubility 21
Solubilization by surfactants 21
Spin-assay for drugs 368
Spin-label 368

Standard reference methods for testing the bioavailability 204
Steady-state drug concentrations 33
Sterility 244
Streptokinase 232
k-Strophanthin 235
Studies in intact animals 55
Sulfamethizole (blood level and urinary excretion) 190
Sulfonamide 368

Tabernanthine 235
Tablet disintegration 55
Tablet disintegration device 55
Tetrabenazine 300
Tetracycline 55
Tetracycline hydrochloride 118
Theophylline 280
Therapeutic efficacy 33
Therapeutic equivalence 215
Therapeutic index 33
Thiry-vella chronic intestinal loops 55
Thyroid function 300
Time course of drug action 33
Tumors, drug disposition 311
Tumors, drug elimination 311
^{14}C-Tyrosine 291
Tyrosine 361

Ulcerogenic effect 321
Urea 244
Uremia 118
Urinary excretion studies 55
Urinary levels 44
Urokinase 232

Validity of measurements 44
Volume of distribution 118, 181



Pharmacology Vol. 8, 1972

Vol. 8, 1972

Pharmacology

International Journal of Experimental and Clinical Pharmacology

Editors

B. B. Brodie, Bethesda, Md.
R. Domenjoz, Bonn
E. Vesell, Hershey, Pa.

Editorial Staff

G. L. Gessa, Cagliari
B. Holmstedt, Stockholm
K. Karzel, Bonn
O. Kraupp, Wien
P. Lechat, Paris
E. G. McQueen, Dunedin
K. Mörsdorf, Bonn
F. Sjöqvist, Stockholm
G. Zbinden, Zürich
G. Zetler, Lübeck

S. Karger · Basel · München · Paris · London · New York · Sydney

S. Karger · Basel · München · Paris · London · New York · Sydney
Arnold-Böcklin-Strasse 25, 4011 Basel (Switzerland)

All rights, including those of translation into other languages, reserved.
Photomechanical reproduction (photocopy, microcopy) of this volume or parts thereof
without special permission of the publishers is prohibited.

© Copyright 1972 by S. Karger AG, Verlag für Medizin und Naturwissenschaften, Basel
Printed in Switzerland by Thür-Offsetdruck, Birsfelden

Contents

AUERSWALD, W. and DOLESCHEL, W.: The Activating Mechanism of Human Plasminogen Through Streptokinase. Inhibition Experiments with BAL 232

BARTOŠEK, I.; GUAITANI, A., and GARATTINI, S.: Long-Term Perfusion of Isolated Rat Liver 244

BERGAN, T.; TOLÅS, T., and ØYDVIN, B.: Influence of Food and Hepatobiliary Disease on the Excretion of Josamycin 336

CHIGNELL, C. F. and STARKWEATHER, D. K.: A Novel Assay for Erythrocyte Carbonic Anhydrase and Certain Sulfonamide Drugs Employing Spin-Labels 368

COLEONI, A. H.: Effects of the Administration of Catecholamine-Depleting Drugs on the Thyroid Function of the Rat 300

COLOMBO, T.: see DONELLI, M. G.

CUCINELL, S. A.: see TJANDRAMAGA, T. B.

DAYTON, P. G.: see TJANDRAMAGA, T. B.

DENKO, C. W.; MOSKOWITZ, R. W., and HEINRICH, G.: Interrelated Pharmacologic Effects of Prostaglandins and Bradykinin 353

DI SALLE, E.: see JORI, A.

DOLESCHEL, W.: see AUERSWALD, W.

DOMINO, E. F.: see HITZEMANN, R. J.

DONELLI, M. G.; COLOMBO, T.; FORGIONE, A., and GARATTINI, S.: Distribution of 6-Mercaptopurine in Tumor-Bearing Animals 311

EBERT, R.: see MENGEL, K.

EVANS, G. H.: see SHAND, D. G.

FORGIONE, A.: see DONELLI, M. G.

GARATTINI, S.: see BARTOŠEK, I.

GARATTINI, S.: see DONELLI, M. G.

GILLERAN, T. G.: see ZAK, S. B.

GUAITANI, A.: see BARTOŠEK, I.

GUTMAN, A. B.: see TJANDRAMAGA, T. B.

HEINRICH, G.: see DENKO, C. W.

HITZEMANN, R. J. and LOH, H. H.: Effect of p-Hydroxynorephedrine (PONE) on the Conversion of ^{3}H-Tyrosine to ^{3}H-Catecholamines 361

HITZEMANN, R. J.; LOH, H. H., and DOMINO, E. F.: Effect of Scopolamine on the Cerebral Accumulation of ^{14}C-Catecholamines from ^{14}C-Tyrosine 291

ISRAILI, Z. H.: see TJANDRAMAGA, T. B.

JORI, A.; DI SALLE, E., and QUADRI, A.: Rate of Aminopyrine Disappearance from Plasma in Young and Aged Humans 273

LEE, C. J.: see VESELL, E. S.

LESSAU, W.: see ZETLER, G.

Loh, H. H.: see Hitzemann, R. J.
Lukas, G.: see Zak, S. B.
Männistö, P. T. and Saarnivaara, L.: Effect of Lithium on the Analgesia Caused by Morphine and Two Antidepressants in Mice 329
Menassé-Gdynia, R.: see Wilhelmi, G.
Mengel, K.; Meyer, P. B.; Ebert, R., and Schwabe, U.: A Comparison of the Antilipolytic Effects of Nicotinic Acid, Methylisoxazole Carboxylic Acid, Methylpyrazole Carboxylic Acid and Insulin in Isolated Fat Cells 280
Meyer, P. B.: see Mengel, K.
Moskowitz, R. W.: see Denko, C. W.
Øydvin, B.: see Bergan, T.
Passananti, G. T.: see Vesell, E. S.
Perel, J. M.: see Tjandramaga, T. B.
Quadri, A.: see Jori, A.
Rangno, R. E.: see Shand, D. G.
Saarnivaara, L.: see Männistö, P. T.
Schwabe, U.: see Mengel, K.
Shand, D. G.; Rangno, R. E., and Evans, G. H.: The Disposition of Propranolol. II. Hepatic Elimination in the Rat 344
Shively, C. A.: see Vesell, E. S.
Starkweather, D. K.: see Chignell, C. F.
Tjandramaga, T. B.; Cucinell, S. A.; Israili, Z. H.; Perel, J. M.; Dayton, P. G.; Yü, T. F., and Gutman, A. B.: Observations on the Disposition of Probenecid in Patients Receiving Allopurinol 259
Tolås, T.: see Bergan, T.
Vesell, E. S.; Lee, C. J.; Passananti, G. T., and Shively, C. A.: Differential Effects of GPA 1851 on Hepatic Microsomal Drug Metabolism Dependent on Dosage and Time of Sacrifice 217
Wilhelmi, G. and Menassé-Gdynia, R.: Gastric Mucosal Damage Induced by Non-Steroid Anti-Inflammatory Agents in Rats of Different Ages ... 321
Yü, T. F.: see Tjandramaga, T. B.
Zak, S. B.; Gilleran, T. G., and Lukas, G.: Interaction of the Imidazolone Derivative GPA 1851 with Hepatic Microsomal Drug Metabolism 222
Zetler, G. and Lessau, W.: Refractory Period and Strophanthin Actions, as Influenced by Four Indole Alkaloids and Two Synthetic Azepinoindoles 235

Proceedings of the Conference on Bioavailability of Drugs at the National Academy of Sciences of the United States, Washington, D.C., November 22–23, 1971 1

Subject Index 377